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Background
Brain ischemia and reperfusion injury leading to tissue de-
generation and loss of neurological function following
return of spontaneous circulation after cardiac arrest (CA) is
a well-known entity. Two landmark trials in 2002 showed
improved survival and neurological outcome of comatose
survivors of out-of-hospital cardiac arrest (OHCA) of pre-
sumed cardiac origin when the patients were subjected to
therapeutic hypothermia of 32 to 34 °C for 12 to 24 hours.
However, the optimal target temperature for these cohorts
is yet to be established and also it is not clear whether strict
fever management and maintaining near normal body
temperature are alone sufficient to improve the outcome.
Methods
Objective: The objective is to determine whether a hypo-
thermic goal of a near-normal body temperature of 36 °C
reduces all-cause mortality compared with a moderate
hypothermia of 33 °C for the unconscious survivors of
OHCA of presumed cardiac origin when subjected ran-
domly to these different targeted temperatures.* Correspondence: Poldermankh@upmc.edu
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controlled trial.
Setting: Thirty-six ICUs in Europe and Australia participated
in this study.
Participants: Unconscious adults (older than 18 years of
age) who survived (Glasgow coma scale less than 8) OHCA
due to presumed cardiac origin with subsequent persistent
return of spontaneous circulation (more than 20 minutes
without chest compressions).
Intervention: The above participant cohorts were randomized
to targeted body temperature of either 33 °C or 36 °C for
36 hours after the CA with gradual rewarming of both groups
to 37 °C (hourly increments of 0.5 °C) after the initial 28 hours.
Body temperatures in both the groups were then main-
tained below 37.5 °C for 72 hours after the initial 36 hours.
Outcomes: Primary outcome measure of all-cause mortality
in both the groups at the end of the trial with the second-
ary outcome measure of all-cause mortality, composite
neurological function as evaluated by cerebral performance
category scale and modified ranking scale at the end of
180 days were studied.
Results
Out of the 939 participants, all-cause mortality at the end of
the trial was 50 % in the 33 °C group (225 of 466 patients)
compared with 48 % in the 36 °C group (235 of 473 patients);
the hazard ratio with a temperature of 33 °C was 1.06 (95 %
confidence interval (CI) 0.89 to 1.28, P= 0.51). At the end of
180 days, 54 % of patients in the 33 °C group versus 52 %
in the 36 °C group had died or had poor neurological
outcome according to cerebral performance category (risk
ratio 1.02, 95 % CI 0.88 to 1.16, P = 0.78) but the modified
ranking scale at the end of 180 days was unchanged (52 %)
in both groups (risk ratio 1.01, 95 % CI 0.89 to 1.14, P = 0.87).his article is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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Maintaining targeted lower normothermia of 36 °C had
similar outcomes compared with induced moderate hypo-
thermia of 33 °C for unconscious survivors of OHCA of pre-
sumed cardiac cause.on clinical parameters and by sensory-evoked potentials
and/or electroencephalogram as indicated.Commentary
Out-of-hospital cardiac arrest (OHCA) is a devastating
and traumatic event for the patient and their family.
Even if the patient survives the initial event the ischemia
and the reperfusion injury lead to tissue destruction and
loss of neuronal function.
One of the major breakthroughs in managing post-
cardiac arrest patients is the implementation of hypo-
thermia, which has shown promising results in improving
neurological function and survival. The earliest recorded
application of therapeutic cooling in medicine dates back
about 5000 years; its use became widespread after publica-
tion of two randomized controlled trials (RCTs) in 2002,
which demonstrated safety and efficacy of mild (32 °C to
34 °C) cooling after cardiac arrest (CA) [1, 2]. These initial
trials were followed by numerous nonrandomized studies
showing improved outcomes when therapeutic hypo-
thermia was introduced [3, 4]. Based on the two RCTs
and subsequent supporting evidence, the International
Liaison Committee on Resuscitation and American Heart
Association guidelines recommend the use of cooling to
32 to 34 °C after witnessed CA when the initial rhythm
was pulseless ventricular tachycardia (VT)/ventricular fib-
rillation (VF) [5]. This was supported by a Cochrane ana-
lysis [6].
However, the evidence underpinning use of hypo-
thermia in CA patients was subsequently criticized. The
largest RCT had excluded more than 90 % of screened pa-
tients and had not applied temperature management in
controls, where the average temperature was 37.8 °C [1];
the other RCT did successfully maintain normothermia in
controls, but here randomization had been by day of the
month instead of per patient [2], and differences in this
(much smaller) study barely achieved statistical signifi-
cance. Harmful effects of fever are well recognized [3];
based on the two RCTs, it could not be ruled out that
strict fever management alone could be sufficient to pre-
vent temperature-induced neurological damage.
This led to the initiation of a much larger multicenter
RCT to compare two targeted temperature regimens
(mild hypothermia of 33 °C versus near normal body
temperature of 36 °C) in 939 unconscious survivors of
OHCA of presumed cardiac cause after sustained return
of spontaneous circulation. The intervention period of
36 hours commenced at the time of randomization and
the goal was to achieve the assigned core temperature as
rapidly as possible using different cooling methods andto maintain this temperature for 24 hours, followed by
rewarming at a rate of 0.5 °C per hour to 37 °C and
maintaining this in both groups for another 72 hours.
Recommendation for continuation or withdrawal of
therapy was done in a blinded fashion at 72 hours based
The study found that rates of the primary outcome
measure (death) and secondary outcome measure (poor
neurologic function) did not differ significantly between
the groups. Subgroup analyses did not indicate signifi-
cant benefits from either strategy. Patients presenting
with more severe potential neuronal injury (for example,
those with nonshockable rhythm and longer time to re-
turn of spontaneous circulation) also had no difference
in outcome between interventions. The only difference
in favor of the 33 °C group was in the rates of survival
with excellent outcome (no neurologic residual), which
was 41.6 % versus 39.4 % (P was not significant). The in-
cidence of adverse events also did not differ significantly
except for higher incidence of hypokalemia (P = 0.018)
and nonsignificant trends to higher incidence of hypo-
magnesemia (P = 0.20), hypophosphatemia (P = 0.13) and
pneumonia (P = 0.089) in the 33 °C group.
This study was done with fewer exclusion criteria and
had a much larger study population (939 patients) than
previous trials. In contrast to the previous studies it in-
cluded patients with initial cardiac rhythms other than
VT/VF. Another unique feature of the study is the adop-
tion of a protocol for withdrawal of life-sustaining treat-
ment; it followed the important concept of preventing
fever by actively controlling temperature in both groups
during the first 3 days after CA.
Potential criticisms include a delayed start of cooling,
a prolonged time to target temperature (10 hours) and a
rapid rewarming rate (from 33 °C to 36 °C in 6 hours),
much faster than in previous trials. Although no com-
parative studies assessing optimal rewarming rates after
CA have been performed, animal studies and studies in
patients undergoing cardiac surgery with extracorporeal
circulation strongly suggest that rapid warming can be
harmful, and could negate some or all of the benefits of
therapeutic cooling [7, 8]. As the trial enrolled, on aver-
age, just one patient per center per month it is conceiv-
able that some type of pre-selection occurred, which
could have influenced the results if the selection was not
random [4, 9].
In spite of these potential criticisms, the fact that good
outcome was achieved in just under 50 % of patients in
both groups demonstrates that, in many patients, very
strict fever control (36 °C) alone is sufficient to provide
neuroprotection. The question still remains whether we
can identify specific cohorts of CA patients who need
different depth and duration of temperature management.
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much better outcomes when patients were cooled to
32 °C compared with 34 °C [10]. The targeted temperature
management trial suggests that 33 °C is not better than
36 °C in many patients. The duration of temperature man-
agement also has not been conclusively settled.
Recommendations
CA patients should receive active temperature manage-
ment after resuscitation. The targeted temperature man-
agement trial found that temperatures of 33 °C or 36 °C
yielded similar outcomes, though whether this applies to
all CA patients is controversial. The absence of tem-
perature control, as was the norm before 2002, is linked
to higher mortality and should be avoided.
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